VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

VolitionRx Limited, a multi-national life sciences company developing simple, easy to use blood-based cancer tests, today announced interim results from a 680-subject clinical trial in colorectal cancer. The study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer using Volition’s Nu.Q™ blood test.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free